āĻšā§āĻŽBIIB âĸ NASDAQ
add
āĻŦāĻžāĻ¯āĻŧā§āĻā§āĻ¨
ā§§ā§ā§.ā§Šā§Ē$
āĻāĻŖā§āĻāĻž āĻĒāĻ°ā§:(ā§Ļ.ā§Ļā§Ļ%)ā§Ļ.ā§Ļā§Ļ
ā§§ā§ā§.ā§Šā§Ē$
āĻŦāĻ¨ā§āĻ§ āĻāĻā§: ā§¨ āĻāĻĒā§āĻ°āĻŋ, ā§Ģ:ā§¨ā§Š:ā§§ā§Ž PM GMT -ā§Ē · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
trending_downāĻ¸āĻŦāĻā§ā§ā§ āĻŦā§āĻļāĻŋ āĻāĻŽā§āĻā§āĻ¸ā§āĻāĻāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻ¤āĻžāĻ˛āĻŋāĻāĻžāĻā§āĻā§āĻ¤ āĻ¸āĻŋāĻāĻŋāĻāĻ°āĻŋāĻāĻŋāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻšā§āĻĄāĻā§ā§āĻžāĻ°ā§āĻāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§Žā§Š.ā§ā§Ž$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§ā§Ŧ.ā§Šā§¯$ - ā§§ā§Žā§¨.ā§¨ā§Š$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§§ā§§ā§Ļ.ā§Ļā§Ē$ - ā§¨ā§Ļā§¨.ā§Ēā§§$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§¨.ā§Ŧā§ĻāĻļāĻ¤Â āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§§ā§Ļ.ā§Ļā§§Â āĻ˛āĻž
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
ā§¨ā§Ļ.ā§§ā§Ž
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻĒā§āĻ°āĻžāĻāĻŽāĻžāĻ°āĻŋ āĻāĻā§āĻ¸āĻā§āĻā§āĻ
NASDAQ
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (USD) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§¨ā§¨ā§.ā§¯ā§Ē āĻā§ | -ā§.ā§§ā§Ē% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§§ā§Šā§Ž.ā§Žā§ŠÂ āĻā§ | -ā§§.ā§Ļā§¯% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§Ē.ā§Žā§¯Â āĻā§ | -ā§§ā§§ā§Ž.ā§Šā§Ē% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | -ā§¨.ā§§ā§Ģ | -ā§§ā§§ā§¯.ā§Žā§Ļ% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§§.ā§¯ā§¯ | -ā§Ēā§¨.ā§§ā§Ģ% |
EBITDA | ā§Ŧā§Ē.ā§ā§¯Â āĻā§ | -ā§Ŧ.ā§¯ā§Ž% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | ā§§ā§¨.ā§Ŧā§Ž% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (USD) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§Šā§Žā§§.ā§Ģā§Â āĻā§ | ā§Ŧā§Ļ.ā§Ŧā§Ŧ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§¨.ā§¯ā§ĒāĻļāĻ¤Â āĻā§ | ā§Ē.ā§¯ā§Ŧ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§§.ā§§ā§¨āĻļāĻ¤Â āĻā§ | -ā§§.ā§Šā§Š% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§.ā§Žā§ŠāĻļāĻ¤Â āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§§ā§Ē.ā§Ŧā§ŽÂ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§§.ā§Ēā§Ž | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Š.ā§Žā§¨% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | ā§Ē.ā§Ģā§Ļ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (USD) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§Ē.ā§Žā§¯Â āĻā§ | -ā§§ā§§ā§Ž.ā§Šā§Ē% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§Ģā§§.ā§§ā§¯Â āĻā§ | -ā§Šā§¨.ā§ā§¨% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§§ā§¨ā§Š.ā§§ā§Â āĻā§ | -ā§Ŧ,ā§Ģā§¨ā§¨.ā§Ļā§Ē% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§§ā§Š.ā§ā§Ļ āĻā§ | -ā§§,ā§Žā§Šā§Ē.ā§§ā§Ž% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§Žā§Ģ.ā§Ēā§ŠÂ āĻā§ | -ā§¨ā§¨ā§Ŧ.ā§Ēā§§% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§¨ā§Š.ā§Ēā§ŠÂ āĻā§ | -ā§Ģā§Ŧ.ā§ā§Ŧ% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
āĻ¸āĻŋāĻāĻ
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§§ā§¯ā§ā§Ž
āĻ¸āĻĻāĻ° āĻĻāĻĒā§āĻ¤āĻ°
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§,ā§Ģā§Ļā§Ļ
